MONROVIA, CA, March 19, 2009
/24-7PressRelease/ -- Dr. Joseph Bolen, Chief Scientific Officer of Millennium Pharmaceuticals, Inc. will be the keynote speaker at GTCbio's 4th Annual Protein Kinases in Drug Discovery Conference taking place on May 4-5, 2009 in Boston, Massachusetts.
Dr. Bolen will deliver his keynote address entitled "Preclinical Imperatives for Translational Continuity in the Clinical Development of Protein Kinase Inhibitors" at this year's conference. The presentation will highlight the importance of aligning disease and treatment hypotheses with kinase drug action in the context of early clinical trials. Dr. Bolen will discuss what the minimum quantitative and qualitative correlations are to provide a knowledge base sufficient to enhance the accuracy of critical decision making during the translational phase of drug assessment.
Dr. Bolen joined Millennium in 1999 as Vice President of Oncology and was promoted to Senior Vice President of Discovery Research in 2002. In this role, he headed all biological research in the areas of oncology, inflammation, metabolic disease and cardiovascular disease as well as all genomics, informatics and platform technologies. In 2003 Dr. Bolen was appointed Senior Vice President of Research and Drug Discovery, a role in which he headed all biological research and related functions as well as all drug discovery functions. Dr. Bolen was appointed Chief Scientific Officer in 2006.
The 4th Annual Protein Kinases in Drug Discovery Conference taking place on May 4-5, 2009 in Boston, Massachusetts will cover topics such as Drug Design Trends, Overcoming Challenges of Kinase Drug Development, Case Studies on Taking Pre-Clinical Kinase Targets to Clinical trials, and Novel Kinases and Inhibitor Candidates.
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=149
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Rania Hafez:- Allergan and CMO at Altheos to speak at Ocular Drug Discovery conference Feb 27-28, 2012 Las Vegas
- AstraZeneca, GSK to speak at Anti-infectives Partnering meeting Nov 7-8, Boston
- Glenn D. Prestwich to speak at 7th Modern Drug Discovery Summit Oct 19-21 2011 in San Diego, CA
- Vice President at Johnson and Johnson to speak at Modern Drug Summit Oct 19-21 2011 in San Diego, CA
- Biosimilars and FDA talk at 4th Protein Discovery & Therapeutics Conference Oct 19-21 in San Diego
- Dr. Joseph Joyce, Director At Merck & Co., To Speak At Vaccines Meeting On Nov. 7-8 In Boston, MA.
- Klarquist Sparkman to speak at 4th Protein Discovery & Therapeutics Meeting Oct 19-21 in San Diego
- Dr. Philip Dormitzer, Head at Novartis, to Speak at Vaccines Meeting on Nov. 7-8 in Boston, MA
- Klaus Mendla, Global Head at Boehringer to speak at CNS Partnering meeting Sept 22-23, San Francisco
- Dr. Kanta Subbarao, Chief at the NIH, to speak at vaccines meeting on Nov. 7-8 in Boston, MA
